Immuron (IMRN) provides an update on research collaboration with the Naval Medical Research Center (NMRC), previously announced in October 2019.
Immuron has executed a research agreement with
Australia’s national science agency, CSIRO to produce the new
therapeutic against Campylobacter and Entero-Toxigenic Escherichia
coli (ETEC) for clinical evaluation by the US Department of Defense.
The NMRC has submitted the Pre-IND information package to the FDA.
CSIRO has been engaged to produce a hyper-immune
bovine colostrum product using vaccines developed by the NMRC. The
current program is back on track and bovine colostrum is expected to be
harvested in September 2020.
The company has also fully executed the Research
Subaward Agreement with The Henry M. Jackson Foundation for advancement
of Military Medicine Inc.
The drug substance and drug product will be
manufactured by the year end and NMRC plans to initiate clinical
development program to prevent acute infectious diarrhea early next
year.
https://seekingalpha.com/news/3584462-immuron-teams-up-aussie-agency-to-develop-therapeutic-for-gut-mediated-pathogens
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.